Ayala Pharmaceuticals (ADXS) News Today → Better than Bitcoin? The Biotech Stock with 46,751% Potential (From Behind the Markets) (Ad) Free ADXS Stock Alerts $0.56 +0.01 (+1.83%) (As of 04/26/2024 ET) Add Compare Share Share HeadlinesStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesSEC FilingsSocial MediaStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesSEC FilingsSocial Media All Sources Trusted Sources MarketBeat.com Benzinga Bloomberg MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha The Street The Wall Street Journal Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative SourceHeadlineAyala Pharmaceuticals (NASDAQ:ADXS) Research Coverage Started at StockNews.comamericanbankingnews.com - April 24 at 2:30 AMStockNews.com Initiates Coverage on Ayala Pharmaceuticals (NASDAQ:ADXS)americanbankingnews.com - April 16 at 2:16 AMImmunome: An Oncology Powerhouse In The Makingseekingalpha.com - April 2 at 7:30 PMAyala Pharmaceuticals Announces Completion of Sale of AL102 to Immunomeglobenewswire.com - March 26 at 8:00 AMIMNM Oct 2024 22.500 callfinance.yahoo.com - March 16 at 9:25 AMIMNM Oct 2024 25.000 callfinance.yahoo.com - March 16 at 8:01 AMIMNM Oct 2024 25.000 putfinance.yahoo.com - March 16 at 8:01 AMIMNM Oct 2024 45.000 callfinance.yahoo.com - March 16 at 7:48 AMImmunome Recognizes Ayala Pharmaceuticals' Announced Completion of Enrollment in Phase 3 RINGSIDE Study Evaluating AL102 in Desmoid Tumorsbusinesswire.com - February 20 at 8:15 AMAdvaxis Executes Strategic Unregistered Equity Salesmsn.com - February 10 at 8:13 AMAdvaxis Announces Definitive Agreement with Ayala Pharmaceuticalsmsn.com - February 7 at 7:56 AMImmunome to buy AL102, a phase 3 asset for treatment of desmoid tumorsmsn.com - February 6 at 9:03 AMImmunome to Acquire AL102, a Phase 3 Asset for the Treatment of Desmoid Tumors, From Ayala Pharmaceuticalsfinance.yahoo.com - February 6 at 8:10 AMAyala Pharmaceuticals Inc Ordinary Shares ADXSmorningstar.com - November 24 at 7:40 AMAyala Pharmaceuticals: Fiscal Q4 Earnings Snapshotsfgate.com - November 20 at 1:03 PMLadenburg Thalmann Downgrades Ayala Pharmaceuticals (ADXS)msn.com - November 17 at 6:25 PMAyala Pharmaceuticals Presents Updated AL102 Results from Phase 2 Clinical Trial in Desmoid Tumors at ESMO Congress 2023finance.yahoo.com - October 23 at 7:30 AMAyala Pharmaceuticals Announces Closing of Merger with Biosightfinance.yahoo.com - October 19 at 8:13 AMAyala Pharmaceuticals Announces Second Quarter 2023 Financial Results and Provides Corporate Updatefinance.yahoo.com - August 10 at 4:46 PMAyala Pharmaceuticals Inc (ADXS)investing.com - August 3 at 8:40 AMAyala Pharmaceuticals Announces Abstracts on AL102 and AL101 Accepted for Presentation at ESMO Congress 2023finance.yahoo.com - August 1 at 4:17 PMAyala Pharmaceuticals and Biosight Enter into Definitive Merger Agreementfinance.yahoo.com - July 27 at 9:00 AMAyala Pharmaceuticals Announces Successful End-of-Phase 2 Meeting with FDA Regarding AL102 for the Treatment of Desmoid Tumorsfinance.yahoo.com - July 5 at 8:13 AMUpdated RINGSIDE Phase 2 Results Featured in Poster Discussion Session at 2023 American Society of Clinical Oncology (ASCO) Annual Meetingfinance.yahoo.com - June 5 at 8:07 AMAyala Pharmaceuticals Announces Updated RINGSIDE Phase 2 Results at 2023 American Society of Clinical Oncology (ASCO) Annual Meetingfinance.yahoo.com - May 25 at 5:12 PMAyala Pharmaceuticals Announces First Quarter 2023 Financial Results and Provides Corporate Updatefinance.yahoo.com - May 23 at 1:41 PMArmando Ayalahealth.usnews.com - May 20 at 7:04 PMAyala Pharmaceuticals Announces RINGSIDE Results to be Presented at the 2023 American Society of Clinical Oncology (ASCO) Annual Meetingfinance.yahoo.com - April 27 at 8:09 AMAyala Pharmaceuticals, Inc. (ADXS)uk.finance.yahoo.com - April 13 at 3:29 PMHubei Biocause Pharmaceuticalforbes.com - April 12 at 2:09 AMAyala Pharmaceuticals Announces Continuation of RINGSIDE Phase 2/3 Study in Desmoid Tumors Following Recommendation of Independent Data Monitoring Committeefinance.yahoo.com - March 3 at 3:52 PMAyala Pharmaceuticals Reports Financial Results For the Fiscal Year Ended October 31, 2022finance.yahoo.com - February 10 at 7:26 AMAdvaxis and Ayala Pharmaceuticals Complete Mergerfinance.yahoo.com - January 19 at 9:45 AMAdvaxis, Inc. (ADXS) Stock Historical Prices & Data - Yahoo Financefinance.yahoo.com - December 25 at 10:20 PMForm 8-K Advaxis, Inc. For: Oct 18 - StreetInsider.comstreetinsider.com - October 20 at 5:24 AMRedHill Biopharma Shares Surge New Treatment Patent For Its Late-Stage COVID-19 Candidate - Yahoo Financefinance.yahoo.com - October 20 at 1:52 AMADVAXIS, INC. : Entry into a Material Definitive Agreement, Regulation FD Disclosure (form 8-K) - Marketscreener.commarketscreener.com - October 19 at 4:37 PMWhy United Airlines Shares Are Trading Higher? Here Are 43 Stocks Moving In Wednesday’s Mid-Day Session - - Benzingabenzinga.com - October 19 at 2:31 PMAYLA Stock Alert: Halper Sadeh LLC Is Investigating Whether the Merger of Ayala Pharmaceuticals, Inc. Is Fair to Shareholders - Business Wirebusinesswire.com - October 19 at 11:36 AMAyala, Advaxis Merge - Baystreet.cabaystreet.ca - October 19 at 11:08 AMAyala Pharmaceuticals, Advaxis to Combine in Stock Deal >AYLA ADXS - MarketWatchmarketwatch.com - October 19 at 11:08 AMAyala Pharmaceuticals and Advaxis Enter into Merger Agreement - Yahoo Financefinance.yahoo.com - October 19 at 8:37 AMAyala stock rises 16% on all-stock merger with Advaxis to focus on cancer drugs - Seeking Alphaseekingalpha.com - October 19 at 7:14 AMAdvaxis and Ayala Pharmaceuticals Enter into Merger Agreement - GlobeNewswireglobenewswire.com - October 19 at 6:36 AMRich Insights into the Metastatic Urothelial Carcinoma Clinical Trial Analysis Featuring 40+ Companies and Therapies | DelveInsight - GlobeNewswireglobenewswire.com - October 17 at 4:21 PMHerbal Medicinal Products Market Is Expected to Grasp the Value of USD 177.65 Billion with Growing CAGR of 6.83% by 2029, Size, Shares, Trends, Growth and Revenue Outlook - GlobeNewswireglobenewswire.com - October 13 at 9:32 AMBlueSphere Bio Appoints Keir Loiacono as Chief Executive Officer - Yahoo Financefinance.yahoo.com - October 4 at 11:07 PMBlueSphere Bio Appoints Keir Loiacono as Chief Executive Officer - Benzingabenzinga.com - October 4 at 10:41 AMReunion Neuroscience (REUN) Appoints Greg Mayes as President and CEO - StreetInsider.comstreetinsider.com - September 28 at 8:14 PMReunion Neuroscience Inc. Appoints Greg Mayes as President and Chief Executive Officerfinance.yahoo.com - September 28 at 10:13 AM Get Ayala Pharmaceuticals News Delivered to You Automatically Sign up to receive the latest news and ratings for ADXS and its competitors with MarketBeat's FREE daily newsletter. Email Address Protect Yourself While There’s Still Time … (Ad)The next step of the Fed's control is here. Section 702 of the Foreign Intelligence Surveillance Act was renewed for two more years and passed into law earlier this week. Allowing the Fed to tighten its grip on your personal privacy and freedom. 4 simple steps to protect your privacy and money before it’s too late. ADXS Media Mentions By Week ADXS Media SentimentLearn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. ADXS News Sentiment▼0.000.32▲Average Medical News Sentiment ADXS News CoverageLearn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. ADXS Articles This Week▼10▲ADXS Articles Average Week Get Ayala Pharmaceuticals News Delivered to You Automatically Sign up to receive the latest news and ratings for ADXS and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies: Can-Fite BioPharma News eFFECTOR Therapeutics News Tenax Therapeutics News Cadrenal Therapeutics News Trevena News Chemomab Therapeutics News Shuttle Pharmaceuticals News Universe Pharmaceuticals News Hillstream BioPharma News Pasithea Therapeutics News Headlines Tools: Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:ADXS) was last updated on 4/26/2024 by MarketBeat.com Staff From Our PartnersThese AI trades triggered this morning (545% return)Prosper Trading AcademyConflict In Israel Sends Gold Soaring ???? Here’s How To Get Your ShareColonial MetalsForget AI, Imperium Is Expected to Grow 320,00% in 3 YearsBanyan Hill PublishingDid You Get Your Free Bitcoin Yet?Crypto Swap ProfitsThe A.I. story nobody is telling you (Read ASAP)TradeSmithFed launches fourth dollar overhaulStansberry ResearchMan Who Predicted 2008: “This Will be Worse.”AltimetryJeff Bezos Just Humiliated Elon MuskInvestorPlace Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Ayala Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
